Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/16/2025

Combining Bupropion and Escitalopram for Depression

Efficacy and Safety

  • When augmenting SSRI treatment that has failed, bupropion decreases depression severity more effectively than buspirone and causes fewer discontinuations due to adverse events, as recommended by Praxis Medical Insights 1
  • Begin with escitalopram monotherapy at standard doses (10-20 mg/day) for 4-8 weeks, as suggested by the American Academy of Family Physicians and the American College of Physicians 2, 3
  • If response is inadequate, add bupropion-SR starting at 150 mg/day and titrate to 300-400 mg/day based on response and tolerability, as recommended by Praxis Medical Insights 1

Special Considerations

  • Bupropion provides dual benefit for patients with depression who also need smoking cessation support, as it is FDA-approved for both depression and smoking cessation, according to Praxis Medical Insights 1
  • The American Diabetes Association recommends monitoring blood pressure and heart rate when using bupropion, particularly in combination with other antidepressants, though neither bupropion nor escitalopram causes significant cardiovascular effects in most patients 4, 1
  • Observe patients for neuropsychiatric adverse effects including suicidal thoughts and behaviors, especially in individuals younger than 24 years, as bupropion carries a black box warning for this population, as noted by the American Diabetes Association and the American Gastroenterological Association 4, 5

Treatment Duration and Special Populations

  • Treatment for a first episode of major depression should last at least 4 months; patients with recurrent depression may benefit from prolonged treatment, as recommended by the American Academy of Family Physicians 2
  • The American College of Physicians suggests that escitalopram is a preferred agent for older patients with depression due to favorable tolerability profiles, though second-generation antidepressants show equal efficacy across age groups 2, 8